We reveal that MECOM-mediated transcriptional regulation of KRAS activates KRAS/ERK/EGR1 signaling axis, contributing to MECOM’s oncogenic activity in MECOM-dependent ovarian cancers. Here, KRAS is linked to ovarian carcinoma.